Renaissance Pharma's daretabart secures FDA Breakthrough status in paediatric neuroblastoma
Essential Pharma's Renaissance Pharma unit has won a US regulatory designation for its anti-GD2 antibody in frontline high-risk childhood cancer, though the drug has no marketing clearance anywhere.
Renaissance Pharma, part of Essential Pharma, has added a regulatory milestone to its paediatric oncology pipeline. On 16 November 2026 the company said the US Food and Drug Administration had given daretabart, an anti-GD2 antibody, Breakthrough Therapy Designation. The label applies to the antibody combined with induction chemotherapy as initial treatment for children whose high-risk neuroblastoma has just been diagnosed.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.